Article
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.
American journal of hematology - 1 Apr 2026
Gangat Naseema, Warraich Momna, Kumar Sudhesh, Fatima Mahnoor, McCullough Kristen, Begna Kebede H, Al-Kali Aref, Patnaik Mrinal M, Hogan William J, Mangaonkar Abhishek, Saliba Antoine N, Torghabeh Mehrdad Hefazi, Alkhateeb Hassan, Shah Mithun V, Foran James M, Badar Talha, Palmer Jeanne M, Yi Cecilia Arana, Pardanani Animesh, Tefferi Ayalew
Abstract excerpt
Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP).
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.